Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab (AMG 145) in Heterozygous Familial Hypercholesterolemia
NCT01375751Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2011
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of evolocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Amgen. Started Aug 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01375751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375751.